What bacteria does cefdinir typically cover (its usual spectrum of activity)?
Cefdinir is an oral, third-generation cephalosporin. Its activity is generally strongest against common respiratory pathogens and some Gram-positive and Gram-negative bacteria.
In practice, cefdinir is used to treat infections caused by many susceptible strains of:
- Streptococcus species (including some strains of Streptococcus pneumoniae)
- Haemophilus influenzae (including many beta-lactamase–producing strains)
- Moraxella catarrhalis (including many beta-lactamase–producing strains)
- Some Enterobacteriaceae (coverage can vary by species and local resistance patterns)
Which respiratory infections is cefdinir commonly used for?
Because of its typical activity against respiratory Gram-positive cocci and respiratory Gram-negative rods, cefdinir is commonly prescribed for:
- Acute bacterial rhinosinusitis
- Acute otitis media
- Community-acquired respiratory tract infections where the likely pathogens match cefdinir’s usual coverage
What about “MRSA” and “Pseudomonas”?
Cefdinir is not generally used for:
- Methicillin-resistant Staphylococcus aureus (MRSA), since cephalosporins usually do not reliably cover MRSA
- Pseudomonas aeruginosa, which is typically resistant to many oral cephalosporins, including cefdinir
Does cefdinir cover atypical pneumonia organisms?
Cefdinir is a beta-lactam and does not reliably cover atypical respiratory pathogens (such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella species). Those organisms usually require different antibiotic classes.
How resistance and susceptibility testing affect the “real” spectrum
The effective spectrum of activity depends on:
- Local resistance rates (especially for beta-lactam resistance)
- The specific organism’s susceptibility (as reported on the antibiogram or culture and susceptibility results)
- Patient factors and site of infection (some pathogens may look “covered” in vitro but still be clinically less responsive)
If you tell me the exact bug you’re targeting (for example, “E. coli,” “H. influenzae,” “S. aureus,” or “S. pneumoniae”) and the infection type (sinusitis, UTI, skin infection, etc.), I can narrow the expected cefdinir coverage more precisely.